Idarubicin, high-dose cytarabine and etoposide for remission induction in therapy-related acute myeloid leukemia

Nicola Philpott*, Jayesh Mehta, Jennie Treleaven, Ray Powles

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

7 Scopus citations

Abstract

Five patients with therapy-related acute myeloid leukemia received combination induction chemotherapy with idarubicin, high-dose cytarabine, and etoposide. Complete remission was achieved in all patients with a single course of therapy. Treatment-related toxicity included nausea, vomiting, mucositis, diarrhea, and liver and kidney function abnormalities, and was low in all patients. There were no deaths during induction therapy. We conclude that this combination is well-tolerated in induction of remission in secondary acute myeloid leukemia, and warrants further assessment because of a very good complete remission rate.

Original languageEnglish (US)
Pages (from-to)127-130
Number of pages4
JournalLeukemia and Lymphoma
Volume15
Issue number1-2
DOIs
StatePublished - Jan 1 1994

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Idarubicin, high-dose cytarabine and etoposide for remission induction in therapy-related acute myeloid leukemia'. Together they form a unique fingerprint.

Cite this